Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Center for Research and Application of Cellular Therapy, Kyoto University Hospital, Kyoto, Japan.
Br J Haematol. 2024 May;204(5):1913-1919. doi: 10.1111/bjh.19372. Epub 2024 Feb 29.
To assess the benefits of HLA-haploidentical haematopoietic stem cell transplantation using post-transplant cyclophosphamide (PTCy-haplo) relative to those of umbilical cord blood (UCB) transplantation in acute lymphoblastic leukaemia (ALL), we analysed 1999 patients (PTCy-haplo, 330; UCB, 1669), using the nationwide Japanese registry. PTCy-haplo was associated with a significantly higher relapse rate, but lower non-relapse mortality, which results in overall survival and disease-free survival, comparable to those of UCB. Among patients in CR1, PTCy-haplo showed a significantly higher survival than UCB regardless of the CD34 cell dose. Our findings provide valuable insights into the donor selection algorithm in allogeneic HSCT for adult patients with ALL.
为了评估在急性淋巴细胞白血病（ALL）中，使用移植后环磷酰胺（PTCy-haplo）的 HLA 单倍体相合造血干细胞移植（haploidentical HSCT）相对于脐带血（UCB）移植的益处，我们使用全国性的日本注册中心分析了 1999 例患者（PTCy-haplo，330 例；UCB，1669 例）。PTCy-haplo 与更高的复发率相关，但非复发死亡率较低，这导致总体生存率和无病生存率与 UCB 相当。在 CR1 患者中，无论 CD34 细胞剂量如何，PTCy-haplo 均显示出比 UCB 更高的生存率。我们的研究结果为成人 ALL 患者异基因 HSCT 中的供者选择算法提供了有价值的见解。
